Home›Gadobenate Dimeglumine

Gadobenate Dimeglumine

Also known as: Multihance

Route: Intravenous

Check Gadobenate Dimeglumine Interactions →

8 interactions on record⛔ Black Box Warning

Gadobenate Dimeglumine has 8 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Cisplatin, Daunorubicin, Doxorubicin. Patients taking Gadobenate Dimeglumine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 8
Moderate: 8

Moderate (8)

Gadobenate Dimeglumine + Cisplatin— MultiHance may compete for MOAT transporter and prolong systemic exposure of cisplatin.
Gadobenate Dimeglumine + Daunorubicin— MultiHance may compete for MOAT transporter and prolong systemic exposure of daunorubicin.
Gadobenate Dimeglumine + Doxorubicin— MultiHance may compete for MOAT transporter and prolong systemic exposure of doxorubicin.
Gadobenate Dimeglumine + Etoposide— MultiHance may compete for MOAT transporter and prolong systemic exposure of etoposide.
Gadobenate Dimeglumine + Methotrexate— MultiHance may compete for MOAT transporter and prolong systemic exposure of methotrexate.
Gadobenate Dimeglumine + Paclitaxel— MultiHance may compete for MOAT transporter and prolong systemic exposure of paclitaxel.
Gadobenate Dimeglumine + Tamoxifen— MultiHance may compete for MOAT transporter and prolong systemic exposure of tamoxifen.
Gadobenate Dimeglumine + Vincristine— MultiHance may compete for MOAT transporter and prolong systemic exposure of vincristine.

Gadobenate Dimeglumine + Cisplatin🟡Moderate

MultiHance may compete for MOAT transporter and prolong systemic exposure of cisplatin.

Gadobenate Dimeglumine + Daunorubicin🟡Moderate

MultiHance may compete for MOAT transporter and prolong systemic exposure of daunorubicin.

Gadobenate Dimeglumine + Doxorubicin🟡Moderate

MultiHance may compete for MOAT transporter and prolong systemic exposure of doxorubicin.

Gadobenate Dimeglumine + Etoposide🟡Moderate

MultiHance may compete for MOAT transporter and prolong systemic exposure of etoposide.

Gadobenate Dimeglumine + Methotrexate🟡Moderate

MultiHance may compete for MOAT transporter and prolong systemic exposure of methotrexate.

Gadobenate Dimeglumine + Paclitaxel🟡Moderate

MultiHance may compete for MOAT transporter and prolong systemic exposure of paclitaxel.

Gadobenate Dimeglumine + Tamoxifen🟡Moderate

MultiHance may compete for MOAT transporter and prolong systemic exposure of tamoxifen.

Gadobenate Dimeglumine + Vincristine🟡Moderate

MultiHance may compete for MOAT transporter and prolong systemic exposure of vincristine.

⛔ FDA Black Box Warning

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. MultiHance is not approved for intrathecal use [see Warnings and Precautions (5.1) ] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of MultiHance in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: chronic, severe kidney disease (GFR <30 mL/min/1.73m 2 ), or acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. For patients at highest risk for NSF, do not exceed the recommended MultiHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration. [see Warnings and Precautions (5.2) ] . WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS See full prescribing information for complete boxed warning Intrathecal administration of gadolinium based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. MultiHance is not approved for intrathecal use. (5.1) GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of MultiHance in these patients unless the diagnostic information is essential and not available with

Contraindications

4 CONTRAINDICATIONS MultiHance is contraindicated in patients with known allergic or hypersensitivity reactions to gadolinium-based contrast agents [see Warnings and Precautions (5.3) ] . MultiHance is contraindicated in patients with known allergic or hypersensitivity reactions to gadolinium-based contrast agents. (4)

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary GBCAs cross the placenta and result in fetal exposure and gadolinium retention. The human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive (see Data ) . In animal reproduction studies, gadobenate dimeglumine has been shown to be teratogenic in rabbits following repeated intravenous administration during organogenesis at doses up to 6 times the recommended human dose. There were no adverse developmental effects observed in rats with intravenous administration of gadobenate dimeglumine during organogenesis at doses up to three times the recommended human dose (see Data ) . Because of the potential risks of gadolinium to the fetus, use MultiHance only if imaging is essential and cannot be delayed. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and is 15 to 20%, respectively. Data Human Data Contrast enhancement is visualized in the placenta and fetal tissues after maternal GBCA administration. Cohort studies and case reports on exposure to GBCAs during pregnancy have not reported a clear association between GBCAs and adverse effects in the exposed neonates. However, a retrospective cohort study, comparing pregnant women who had a GBCA MRI to pregnant women who did not have an MRI, reported a higher occurrence of stillbirths and neonatal deaths in the group receiving GBCA MRI. Limitations of this study include a lack of comparison with non-contrast MRI and lack of information about the maternal indication for MRI. Overall, these data preclude a reliable evaluation of the potential risk of adverse fetal outcomes with the use of GBCAs in pregnancy. Animal Data Gadolinium Retention GBCAs administered to pre

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.